CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan

Core Viewpoint - CytoSorbents Corporation has received regulatory approval for its CytoSorb therapy in Taiwan, which is aimed at treating critical illnesses by removing harmful substances from the blood, highlighting the therapy's efficacy and the company's commitment to expanding its market presence [1][6]. Group 1: Company Overview - CytoSorbents Corporation (NASDAQ:CTSO) specializes in blood purification technologies for life-threatening conditions in intensive care and cardiac surgery [6][10]. - The company’s flagship product, CytoSorb, is an extracorporeal cytokine adsorber that has been approved in the European Union and is distributed in 75 countries [1][10]. - CytoSorbents has received approximately $50 million in funding from various U.S. government agencies, indicating strong institutional support for its technologies [3]. Group 2: Product and Technology - CytoSorb is designed to reduce cytokine storms and is effective in treating conditions such as sepsis, acute respiratory distress syndrome, and liver diseases [1][6]. - The device has been used in over 237,000 cases globally as of March 31, 2024, demonstrating its widespread application and acceptance in critical care [1]. - The technology is based on biocompatible polymer beads that remove toxic substances from blood through pore capture and surface adsorption [3]. Group 3: Market and Collaboration - Hemoscien Corporation will distribute CytoSorb in Taiwan, leveraging its established customer relationships in the region [1][6]. - Taiwan's healthcare system, which serves approximately 24 million inhabitants, is recognized for its advanced medical standards and technology, making it a promising market for CytoSorb [8]. - The partnership aims to address the critical need for effective therapies in Taiwan, where sepsis is a significant health issue with an estimated 150,000 new cases annually and a mortality rate of up to 30% [8][9].